RG-125 / AstraZeneca, Novartis - LARVOL DELTA

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2024 ➔ Mar 2025

Trial completion date • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: AstraZeneca | Completed ➔ Active, not recruiting | Trial completion date: Feb 2022 ➔ Aug 2024

Enrollment closed • Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | Trial completion date: Aug 2022 ➔ Feb 2022

Trial completion • Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Feb 2022 ➔ Aug 2022

Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Aug 2021 ➔ Feb 2022

Clinical • Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Mar 2021 ➔ Aug 2021

Clinical • Trial completion date • Hepatology • Non-alcoholic Steatohepatitis

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=14; Active, not recruiting; Sponsor: AstraZeneca; Trial primary completion date: Dec 2017 ➔ Nov 2018

Clinical • Trial primary completion date • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=51; Active, not recruiting; Sponsor: AstraZeneca; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=14; Active, not recruiting; Sponsor: AstraZeneca; N=51 ➔ 14

Clinical • Enrollment change • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=51; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P1/2 trial • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=51; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=14; Completed; Sponsor: AstraZeneca; Active, not recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Oct 2019; Trial primary completion date: Dec 2020 ➔ Oct 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1/2; N=14; Active, not recruiting; Sponsor: AstraZeneca; Trial completion date: Nov 2018 ➔ Dec 2020; Trial primary completion date: Nov 2018 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease. (clinicaltrials.gov) - P1; N=14; Completed; Sponsor: AstraZeneca; Phase classification: P1/2 ➔ P1

Phase classification • Diabetes • Hepatology • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus • MRI

RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY (EULAR 2019) - "RG6125 was well tolerated with only mild to moderate AEs. RG6125 did not show a discernible treatment effect in RA patients in combination with anti-TNFα-blockers over placebo."

Clinical • P2 data

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: AstraZeneca; Trial primary completion date: Dec 2016 ➔ Nov 2017

Clinical • Trial primary completion date